26 results
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
9 May 24
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
4:10pm
designation from the European Medicines Agency and the Innovation Passport from the United Kingdom’s Medicines and Healthcare Products Regulatory
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
18 Mar 24
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
4:08pm
the European Medicines Agency and the Innovation Passport from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency
8-K
EX-99.1
zen2f1t0ysb6iuc 0gc
9 Nov 23
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
4:07pm
8-K
EX-99.1
trfg11iiwz7mja0g
10 Aug 23
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
4:09pm
8-K
EX-99.1
bv28v0 oi8p3u7z
11 May 23
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
4:10pm
PRRN14A
gu2wmtmvkwt 7l2
13 Apr 21
Revised preliminary proxy statement filed by non-management
4:16pm
PREC14A
t2i bqypkzp7o5u1d
7 Apr 21
Preliminary proxy with contested solicitation
5:48pm
DFAN14A
EX-99.1
g8gp6d
18 Mar 21
Additional proxy materials by non-management
2:28pm
DEFA14A
2rb5l ho5
17 Mar 21
Additional proxy soliciting materials
5:28pm